A rewrite of Texas’ social studies curriculum is underway, with lawmakers, teachers and history enthusiasts at odds over exactly how to present the history of Texas and the United States to the ...

BOSTON, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...

“BOYS II PLANET” spin-off “PLANET C : HOME RACE” has aired its final episode! “PLANET C : HOME RACE” featured 18 contestants from PLANET C on “BOYS II PLANET” who did not make it to the final group, ...

Praxis Precision Medicines, Inc. (PRAX) stock is soaring in trading today, up 35% at time of writing, with shares reaching a value of $260, their highest value since the beginning of 2022. Current ...

Praxis Precision Medicines Inc. (NASDAQ: PRAX) shares surged 24.81% in pre-market trading on Friday, climbing to $237.10. Check out the current price of PRAX stock here. PRAX closed Thursday's regular ...

The Iowa State Board of Education is considering changes to the social studies curriculum after a new law required a review of curriculum and education standards. The proposed changes include teaching ...

Okay. Good afternoon, everybody. Thank you for joining us. I'm Doug Tsao, Senior Analyst at H.C. Wainwright. We are thrilled today for what I think is a very unique event. We are joined by Professor ...

The elected 15-member board, where Republicans hold a majority, discussed key topics that would fall under a new framework approved in September. Members heard from teachers, parents and students ...

Culper Research report argues that the data underpinning its essential tremor program cannot withstand regulatory scrutiny. According to the short report, Praxis engineered its October 2025 results ...

To better understand which social media platforms Americans use, Pew Research Center surveyed 5,022 U.S. adults from Feb. 5 to June 18, 2025. SSRS conducted this National Public Opinion Reference ...

Shares of biopharmaceutical company Praxis Precision Medicines Inc. soared Thursday, boosted by the successful trial of a new drug to treat movement disorders. The drug, ulixacaltamide, targets ...

Seven months ago, independent clinical trial observers peeked at interim data for Praxis Precision Medicines’ essential tremor drug and recommended stopping the Phase 3 studies. Praxis kept going. On ...